In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada - PubMed (original) (raw)

In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada

Anne-Marie Bourgault et al. Antimicrob Agents Chemother. 2006 Oct.

Abstract

Clostridium difficile isolates from a 2004 outbreak in Québec, Canada, were all found to be susceptible to metronidazole, vancomycin, rifampin, and meropenem but resistant to bacitracin, cefotaxime, ciprofloxacin, and levofloxacin, and most (>80%) were resistant to ceftriaxone, clarithromycin, gatifloxacin, and moxifloxacin. The predominant NAP1 isolates were susceptible to clindamycin, while the NAP2 isolates were resistant.

PubMed Disclaimer

Similar articles

• Clostridium difficile infections in a Shanghai hospital: antimicrobial resistance, toxin profiles and ribotypes.
  Huang H, Wu S, Wang M, Zhang Y, Fang H, Palmgren AC, Weintraub A, Nord CE. Huang H, et al. Int J Antimicrob Agents. 2009 Apr;33(4):339-42. doi: 10.1016/j.ijantimicag.2008.09.022. Epub 2008 Dec 20. Int J Antimicrob Agents. 2009. PMID: 19097757
• Diversity of moxifloxacin resistance during a nosocomial outbreak of a predominantly ribotype ARU 027 Clostridium difficile diarrhea.
  Carman RJ, Genheimer CW, Rafii F, Park M, Hiltonsmith MF, Lyerly DM. Carman RJ, et al. Anaerobe. 2009 Dec;15(6):244-8. doi: 10.1016/j.anaerobe.2009.09.009. Epub 2009 Oct 8. Anaerobe. 2009. PMID: 19818865
• [Epidemiological study of Clostridium difficile strains isolated in Jean-Verdier-René-Muret hospitals from 2001 to 2007].
  Poilane I, Fantinato C, Cruaud P, Collignon A. Poilane I, et al. Pathol Biol (Paris). 2008 Nov-Dec;56(7-8):412-6. doi: 10.1016/j.patbio.2008.07.009. Epub 2008 Oct 7. Pathol Biol (Paris). 2008. PMID: 18842360 French.
• Clostridium difficile and fluoroquinolones: is there a link?
  Weiss K. Weiss K. Int J Antimicrob Agents. 2009 Mar;33 Suppl 1:S29-32. doi: 10.1016/S0924-8579(09)70013-5. Int J Antimicrob Agents. 2009. PMID: 19303566 Review.
• Antimicrobial resistance in Clostridium difficile.
  Huang H, Weintraub A, Fang H, Nord CE. Huang H, et al. Int J Antimicrob Agents. 2009 Dec;34(6):516-22. doi: 10.1016/j.ijantimicag.2009.09.012. Epub 2009 Oct 13. Int J Antimicrob Agents. 2009. PMID: 19828299 Review.

Cited by

• An epidemiological surveillance study (2021-2022): detection of a high diversity of Clostridioides difficile isolates in one tertiary hospital in Chongqing, Southwest China.
  Cui Y, Zhang C, Jia Q, Gong X, Tan Y, Hua X, Jian W, Yang S, Hayer K, Raja Idris RK, Zhang Y, Wu Y, Tu Z. Cui Y, et al. BMC Infect Dis. 2023 Oct 19;23(1):703. doi: 10.1186/s12879-023-08666-2. BMC Infect Dis. 2023. PMID: 37858038 Free PMC article.
• Clostridioides difficile carriage in animals and the associated changes in the host fecal microbiota.
  Thanissery R, McLaren MR, Rivera A, Reed AD, Betrapally NS, Burdette T, Winston JA, Jacob M, Callahan BJ, Theriot CM. Thanissery R, et al. Anaerobe. 2020 Dec;66:102279. doi: 10.1016/j.anaerobe.2020.102279. Epub 2020 Oct 3. Anaerobe. 2020. PMID: 33022384 Free PMC article.
• Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis.
  Sholeh M, Krutova M, Forouzesh M, Mironov S, Sadeghifard N, Molaeipour L, Maleki A, Kouhsari E. Sholeh M, et al. Antimicrob Resist Infect Control. 2020 Sep 25;9(1):158. doi: 10.1186/s13756-020-00815-5. Antimicrob Resist Infect Control. 2020. PMID: 32977835 Free PMC article. Review.
• Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027.
  Peng Z, Simeon R, Mitchell SB, Zhang J, Feng H, Chen Z. Peng Z, et al. mSphere. 2019 Oct 2;4(5):e00596-19. doi: 10.1128/mSphere.00596-19. mSphere. 2019. PMID: 31578248 Free PMC article.
• Evidence of transmission of Clostridium difficile in asymptomatic patients following admission screening in a tertiary care hospital.
  Sheth PM, Douchant K, Uyanwune Y, Larocque M, Anantharajah A, Borgundvaag E, Dales L, McCreight L, McNaught L, Moore C, Ragan K, McGeer A, Broukhanski G. Sheth PM, et al. PLoS One. 2019 Feb 11;14(2):e0207138. doi: 10.1371/journal.pone.0207138. eCollection 2019. PLoS One. 2019. PMID: 30742636 Free PMC article.

References

1. 1. Barbut, F., G. Corthier, and Y. Charpak. 1996. Prevalence and pathogenicity of Clostridium difficile in hospitalized patients: a French multicenter study. Arch. Intern. Med. 156:1449-1454. - PubMed
2. 1. Bartlett, J. G., and T. M. Perl. 2005. The new Clostridium difficile—what does it mean? N. Engl. J. Med. 353:2503-2505. - PubMed
3. 1. Contant, C., D. Olden, J. Bell, and J. D. Turnidge. 1996. Disk diffusion interpretive criteria for fusidic acid susceptibility for testing of staphylococci by the National Committee for Clinical Laboratory Standards method. Diagn. Microbiol. Infect. Dis. 25:9-13. - PubMed
4. 1. Fawley, M., and M. H. Wilcox. 2002. Pulsed-field gel electrophoresis can yield DNA fingerprints of degradation-susceptible Clostridium difficile strains. J. Clin. Microbiol. 40:3546-3547. - PMC - PubMed
5. 1. Freeman, J., and M. H. Wilcox. 2001. Antibiotic activity against genotypically distinct and indistinguishable Clostridium difficile isolates. J. Antimicrob. Chemother. 47:244-246. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information